molecules of the month


IV CaSR agonist

Ph. III candidate in secondary hyperparathyroidism

identified from "kokumi-flavor" studies of peptides

Mol. Pharmacol.

Sanwa Kagaku Kenkyusho, Mie, JP

Upacicalcet chemical structure IV CaSR agonist - Sanwa Kagaku Kenkyusho, Mie, JP
3 mins read

Context. Upacicalcet (Sanwa Kagaku Kenkyusho Co) is a calcium-sensing receptor (CaSR) agonist being developed for secondary hyperparathyroidism (SHPT). The IV drug, first identified in "kokumi-flavor" studies of γ-glutamyl peptides, was approved for SHPT in Japan in 2021 and is currently being developed for the US and other markets. Upacicalcet, like other calcimimetics, acts as a positive allosteric modulator of CaSR and activates the expression of parathyroid hormone. However, unlike the other drugs, such as the widely studied cinacalcet and the recently approved etelcalcetide, upacicalcet has a unique binding method resulting in strong positive allosteric activity. Sanwa Kagaku Kenkyusho scientists believe that this novel binding mode will make the drug a new option for patients whose existing therapies are ineffective, such…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: